Zevra Therapeutics Inc Revenue Growth Rates (ZVRA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Zevra Therapeutics Inc   (NASDAQ: ZVRA)
 

ZVRA's Revenue Growth by Quarter and Year

Zevra Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ZVRA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 39.66
1st Quarter March 29.00
FY 68.66

ZVRAs Annual Revenue
Zevra Therapeutics Inc 's Revenue in the fiscal year 2025 $ 106.47 millions
Zevra Therapeutics Inc 's Revenue in the fiscal year 2024 $ 23.61 millions
Zevra Therapeutics Inc 's Revenue in the fiscal year 2023 $ 27.46 millions
Zevra Therapeutics Inc 's Revenue in the fiscal year 2022 $ 10.46 millions
Zevra Therapeutics Inc 's Revenue in the fiscal year 2021 $ 28.65 millions




ZVRA Revenue second quarter 2026 Y/Y Growth Comment
Zevra Therapeutics Inc reported Revenue rise of 53.26% year on year in the second quarter 2026, to $ 39.66 millions, this is lower than Zevra Therapeutics Inc 's recent average Revenue rise of 79.55%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue growth. While Zevra Therapeutics Inc ' s Revenue jump of 53.26% ranks overall at the positon no. 325 in the second quarter 2026.


ZVRA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 183.47 % -8.93 % 469.83 %
3rd Quarter September - 604.32 % 27.59 % 1.05 %
2nd Quarter June 53.26 % 481.57 % -47.46 % 551.54 %
1st Quarter March 42.16 % 494.75 % 19.1 % -27.46 %
FY   - 350.76 % -14.02 % -

Financial Statements
Zevra Therapeutics Inc 's second quarter 2026 Revenue $ 39.66 millions ZVRA's Income Statement
Zevra Therapeutics Inc 's second quarter 2025 Revenue $ 25.88 millions Quarterly ZVRA's Income Statement


ZVRA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 30.97 % 225.41 % 355.86 %
3rd Quarter September - 0.7 % -16.85 % -65.76 %
2nd Quarter June 36.77 % 26.86 % 29.74 % 194.1 %
1st Quarter March -15.03 % 69.44 % -74.05 % 24.14 %
FY (Year on Year)   - 350.76 % -14.02 % -


Back to ZVRA Growth rate Comparisons >> Back to ZVRA Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #87
Overall #325

Revenue Y/Y Growth Statistics
High Average Low
350.91 % 79.55 % -65.44 %
(Dec 31 2025)   (Jun 30 2022)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #87
Overall #325
Revenue Y/Y Growth Statistics
High Average Low
350.91 % 79.55 % -65.44 %
(Dec 31 2025)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Zevra Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
412.13 % 52.43 % -88 %
(Mar 31 2021)  


ZVRA's II. Quarter Q/Q Revenue Comment
Zevra Therapeutics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 36.77% quarter on quarter, to $ 39.66 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 26.86% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Zevra Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 308.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #75
Overall #308
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #75
Overall #308
Revenue Q/Q Growth Statistics
High Average Low
412.13 % 52.43 % -88 %
(Mar 31 2021)  


ZVRA's II. Quarter Q/Q Revenue Comment
Zevra Therapeutics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 36.77% quarter on quarter, to $ 39.66 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 26.86% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Zevra Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 308.


Zevra Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 128.86 $ 115.07 $ 106.47 $ 84.39 $ 62.02
Y / Y Revenue Growth (TTM) 107.76 % 183.51 % 350.91 % 240.47 % 158.57 %
Year on Year Revenue Growth Overall Ranking # 106 # 192 # 2202 # 237 # 215
Seqeuential Revenue Change (TTM) 11.98 % 8.08 % 26.17 % 36.07 % 52.8 %
Seq. Revenue Growth (TTM) Overall Ranking # 325 # 113 # 1990 # 1222 # 2224


Cumulative Revenue growth Comment
Assuming the Zevra Therapeutics Inc 's fiscal year would have ended in Jun 30 2026, Zevra Therapeutics Inc would have reprted above average annual Revenue surge of 107.76% year on year, of $ 129 millions.
This marks a slow-down of the companys growth trends and from the 183.51% surge in Mar 31 2026.

Within the Healthcare sector 32 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 106, from total ranking in previous quarter at 192.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 47
Healthcare Sector # 33
Overall # 106

Revenue TTM Y/Y Growth Statistics
High Average Low
350.91 %
 79.55 %
-65.44 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 47
Sector # 87
S&P 500 # 325
Cumulative Revenue growth Comment
Assuming the Zevra Therapeutics Inc 's fiscal year would have ended in Jun 30 2026, Zevra Therapeutics Inc would have reprted above average annual Revenue surge of 107.76% year on year, of $ 129 millions.
This marks a slow-down of the companys growth trends and from the 183.51% surge in Mar 31 2026.

Within the Healthcare sector 32 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 106, from total ranking in previous quarter at 192.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 47
Healthcare Sector # 33
Overall # 106

Revenue TTM Y/Y Growth Statistics
High Average Low
350.91 %
79.55 %
-65.44 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 47
Sector # 87
S&P 500 # 325




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ZVRA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions


About Zevra Therapeutics Inc Revenue Growth Rates (ZVRA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Zevra Therapeutics Inc (CIK 1434647).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001434647-26-000068
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Zevra Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.